For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
UCB announced an additional upgrade to its FY25 financial guidance, where it now expects revenue to exceed € 7.6b, representing +24% y/y (previously at least € 7b), and adj. EBITDA margin to be higher than 31% (previously at least 30%). This is the company's second guidance upgrade this year and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS, as well as a favourable payer m...
Maxeda appoints advisors ahead of talks with creditors (9fin)|Isabel Marant: conference call feedback. The tone remains confident.|The FSB has published an updated list of G-SIB banks - DB faces lower capital surcharge.|MPS chief executive under investigation by Milan public prosecutor|
Maxeda aurait engagé Kirkland & Ellis et Perella Weinberg (9fin)|Isabel Marant: feedback conference call. Le ton reste confiant|Le FSB a publié la liste updatée des banques G-SIBs - DB voit ses exigences baisser.|Le CEO de MPS sous enquête du Procureur de la République de Milan|
VGP and Areim Agree on Third Closing in 50:50 ‘SAGA’ Joint Venture PRESS RELEASE Regulated Information – Inside information Antwerp, Belgium 28 November 2025 (7.00 a.m. CET) VGP NV ('VGP') and AREIM Pan-European Logistics Fund (D) AB, announce an agreement on the third closing between VGP and their 50:50 joint venture, SAGA (The ‘Sixth Joint Venture’). The transaction comprises 17 logistics buildings and a parkhouse in 13 different VGP Parks among which are the first parks in Austria, Spain, Portugal and Italy due to the geographical extension of the joint venture. The transaction is ex...
VGP en Areim Bereiken Akkoord over Derde Closing in 50:50 'SAGA' Joint Venture PERSBERICHT Gereglementeerde informatie - Voorwetenschap Antwerpen, België 28 november 2025(7.00 uur CET) VGP NV ('VGP') en AREIM Pan-European Logistics Fund (D) AB, kondigden vandaag de overeenkomst aan over een derde closing tussen VGP en hun 50:50 joint venture, SAGA (de 'Zesde Joint Venture'). De transactie omvat 17 logistieke gebouwen en één parkeergarage in 13 verschillende VGP-parken waaronder de eerste parken in Oostenrijk, Spanje, Portugal en Italië dankzij de geografische uitbreiding van de joint ven...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.